Subscribe To
Aclaris therapeutics: the many lives of this biopharmaceutical developer
Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps ...
September 28, 2023, 7:18 am
Crane off to a good start and targeting the right opportunities
Crane management has set out a bold vision for remaking this company now that it has split from Crane NXT and is purely focused on industrial and aero...
September 28, 2023, 2:56 am
Elicio therapeutics presents updated preliminary data including promising relapse-free survival data from the phase 1 study of eli-002 at aacr special conference: pancreatic cancer
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G...
September 27, 2023, 9:30 pm
23andme announces poster presentations on 23me-00610, an investigational antibody targeting cd200r1, at the society for immunotherapy of cancer’s (sitc) 2023 annual meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid...
September 27, 2023, 8:05 pm
Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...
September 27, 2023, 8:05 pm
Sagimet biosciences announces completion of enrollment of 120 patients for phase 3 clinical trial by its partner ascletis of denifanstat combined with bevacizumab for treatment of recurrent glioblasto
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...
September 27, 2023, 8:05 pm
Cellectis to present pre-clinical data on multi-armored allogeneic muc1-car t-cells targeting triple-negative breast cancer at the society for immunotherapy of cancer (sitc) 38th annual meeting
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology com...
September 27, 2023, 4:30 pm
Why nextera energy partners stock crashed 17% today
The energy company's management used to tell investors they could expect its distributions to grow by about 12% per year. Now it's...
September 27, 2023, 12:24 pm
Meta platforms: here's what you don't know about meta
We remain buy-rated on Meta Platforms, Inc. We think Meta's FoA customer base and A.I.-enabled interactive services position it for better ad revenue ...
September 27, 2023, 10:51 am
Nzdusd moves toward 200 bar ma on the 4-hour chart.
The NZDUSD is pushing back toward the lows for the day and in the process it is moving back toward the 200 bar MA on the 4-hour chart at 0.5933. Earli...
September 26, 2023, 8:03 pm
Squarespace analysts see above-average growth; shrug off genai discount on stock
BofA Securities analysts believe Squarespace Inc is well positioned to gain share within the website building/hosting market as a design-first platfor...
September 26, 2023, 4:27 pm
Veeco instruments: opportunities across the board and not overvalued
Veeco has been executing better in its core business despite downturns in areas like hard drive capex, and recently won its first laser anneal busines...
September 26, 2023, 1:45 pm
Dyadic and byorna announce a collaboration targeting the production of abundant, low-cost mrna from c1-cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) to...
September 26, 2023, 12:30 pm
Arizona gold & silver reveals plans for upcoming drilling at philadelphia project
Arizona Gold and Silver Inc (TSX-V:AZS) gave investors a peek into preparations for its upcoming drill program at its Philadelphia project in Mohave C...
September 26, 2023, 12:26 pm
Fmr. ftc commissioner thompson on ftc-amazon: lawsuit can send the opposite message if unsuccessful
Mozelle Thompson, former FTC Commissioner under President Clinton, joins 'Squawk Box' to discuss the FTC's forthcoming lawsuit against tech Amazon thi...
September 26, 2023, 9:32 am
Galectin therapeutics to present update on its belapectin liver cirrhosis program at the 20th edition of discovery on target meeting, in boston, september 25-28, 2023
NORCROSS, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target gale...
September 26, 2023, 8:00 am
Analyzing natural gas: bullish potential vs. bearish risks
Natural gas remains in consolidation, with potential for an acceleration in price upon breaking above 2.68, ta...
September 25, 2023, 8:13 pm
Build-a-bear workshop: financial fortitude, priced at 6x operating profits
Build-A-Bear Workshop, Inc.'s unique value proposition builds strong emotional connections with customers through its brand and stuffed animals. The c...
September 25, 2023, 1:48 pm
Regeneron completes acquisition of decibel therapeutics, adding promising gene therapy programs for hearing loss
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed...
September 25, 2023, 12:34 pm
4d molecular therapeutics: some failures, a few key successes
4D Molecular Therapeutics, Inc. has faced setbacks, with the FDA placing a clinical hold on its Fabry Disease program due to serious kidney conditions...
September 25, 2023, 12:19 pm